Zydus Lifesciences launches ANVIMO
ANVIMO will be available in dosages of 240 mg and 480 mg
ANVIMO will be available in dosages of 240 mg and 480 mg
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Emcure has launched an awareness campaign to help spread the word about male anemia
Modernization and supply chain diversity drive new growth
Mahatma Gandhi Cancer Hospital & Research Institute has emerged as the leading provider of comprehensive cancer care in Viza
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Subscribe To Our Newsletter & Stay Updated